The team performed anchored multiplex PCR-based next-generation sequencing on 26 genes linked to sarcomas, comparing the method to standard diagnostic tools.
The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
The firm has inked a number of significant deals over the past year and presented research involving new assays at last week's American Molecular Pathology meeting.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
